TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.040
0.00 (0.00%)
At close: Mar 20, 2026, 4:00 PM EDT
1.050
+0.010 (0.96%)
After-hours: Mar 20, 2026, 7:13 PM EDT
TScan Therapeutics Employees
TScan Therapeutics had 142 employees as of December 31, 2025. The number of employees decreased by 53 or -27.18% compared to the previous year.
Employees
142
Change
-53
Growth
-27.18%
Revenue / Employee
$72,711
Profits / Employee
-$913,845
Market Cap
59.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 142 | -53 | -27.18% | 142 | 0 |
| Sep 30, 2025 | 148 | -51 | -25.63% | 146 | 2 |
| Jun 30, 2025 | 210 | 22 | 11.70% | 208 | 2 |
| Mar 31, 2025 | 201 | 34 | 20.36% | 200 | 1 |
| Dec 31, 2024 | 195 | 41 | 26.62% | 194 | 1 |
| Sep 30, 2024 | 199 | 44 | 28.39% | 188 | 11 |
| Jun 30, 2024 | 188 | 39 | 26.17% | 175 | 13 |
| Mar 31, 2024 | 167 | 29 | 21.01% | 161 | 6 |
| Dec 31, 2023 | 154 | 16 | 11.59% | 154 | 0 |
| Sep 30, 2023 | 155 | 24 | 18.32% | 145 | 10 |
| Jun 30, 2023 | 149 | 31 | 26.27% | 135 | 14 |
| Mar 31, 2023 | 138 | 33 | 31.43% | 136 | 2 |
| Dec 31, 2022 | 138 | 33 | 31.43% | 137 | 1 |
| Sep 30, 2022 | 131 | 36 | 37.89% | 127 | 4 |
| Jun 30, 2022 | 118 | 43 | 57.33% | 115 | 3 |
| Mar 31, 2022 | 105 | 44 | 72.13% | 104 | 1 |
| Dec 31, 2021 | 105 | 47 | 81.03% | 104 | 1 |
| Sep 30, 2021 | 95 | 37 | 63.79% | 90 | 5 |
| Jun 30, 2021 | 75 | - | - | 73 | 2 |
| Mar 31, 2021 | 61 | - | - | 60 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Fractyl Health | 101 |
| ImmuCell | 84 |
| eXoZymes | 31 |
| Edesa Biotech | 17 |
| ImageneBio | 15 |
| Instil Bio | 14 |
| Alterity Therapeutics | 9 |
TCRX News
- 17 days ago - TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 - GlobeNewsWire
- 24 days ago - TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities - GlobeNewsWire
- 4 months ago - TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 4 months ago - TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 - GlobeNewsWire
- 6 months ago - TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 - GlobeNewsWire